Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

Veru Inc. has pivoted to focus on preventing lean mass reduction in patients using GLP-1 agonists, leveraging its lead asset, enobosarm. A Phase 2b trial showed that a 3mg dose of Enobosarm ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

FTSE Russell has released a preliminary list of companies set to join or leave the Russell 3000 Index as part of its 2025 ...

Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle loss in older adults.

Veru's Phase 2b study shows enobosarm combined with semaglutide improves safety, reduces gastrointestinal issues, and promotes fat loss while preserving lean mass. There is a potential risk that ...

Aronne, MD, an obesity expert, past president of the Obesity Society and a scientific advisor and consultant to Veru. 1 Adverse events (at least 4 subjects in any dose group) from Day 1 to Day ...

--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY ...

Aronne, MD, an obesity expert, past president of the Obesity Society and a scientific advisor and consultant to Veru. 2 Graded as mild in severity, levels returned to below baseline while on drug ...

Veru is also planning to meet with the FDA in Q3 2025 to discuss its Phase 3 trial design, targeting around 400 patients. This article was generated with the support of AI and reviewed by an editor.

FTSE Russell released a preliminary list of companies set to join or leave the Russell Microcap Index as part of its 2025 ...